These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16857292)

  • 1. Engineered antibody therapeutics.
    Mather JP
    Adv Drug Deliv Rev; 2006 Aug; 58(5-6):631-2. PubMed ID: 16857292
    [No Abstract]   [Full Text] [Related]  

  • 2. Humanized antibodies for therapy.
    Co MS; Queen C
    Nature; 1991 Jun; 351(6326):501-2. PubMed ID: 2046753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manufacturing of recombinant therapeutic proteins in microbial systems.
    Graumann K; Premstaller A
    Biotechnol J; 2006 Feb; 1(2):164-86. PubMed ID: 16892246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rapid discovery of engineered antibodies.
    Wang M; He M
    IDrugs; 2007 Aug; 10(8):562-5. PubMed ID: 17665332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of protein therapeutics.
    De Groot AS; Scott DW
    Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guest editor's introduction--antibody engineering.
    Rüker F
    Arch Biochem Biophys; 2012 Oct; 526(2):85-6. PubMed ID: 22944043
    [No Abstract]   [Full Text] [Related]  

  • 7. Considerations for the development of therapeutic monoclonal antibodies.
    Swann PG; Tolnay M; Muthukkumar S; Shapiro MA; Rellahan BL; Clouse KA
    Curr Opin Immunol; 2008 Aug; 20(4):493-9. PubMed ID: 18586093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tailor-made antibody therapeutics.
    Chowdhury PS; Wu H
    Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.
    Weisser NE; Hall JC
    Biotechnol Adv; 2009; 27(4):502-20. PubMed ID: 19374944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody therapeutics: history and future.
    Buss NA; Henderson SJ; McFarlane M; Shenton JM; de Haan L
    Curr Opin Pharmacol; 2012 Oct; 12(5):615-22. PubMed ID: 22920732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aglycosylated antibodies and the methods of making and using them: WO2008030564.
    Jefferis R
    Expert Opin Ther Pat; 2009 Jan; 19(1):101-5. PubMed ID: 19441902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular engineering and design of therapeutic antibodies.
    Presta LG
    Curr Opin Immunol; 2008 Aug; 20(4):460-70. PubMed ID: 18656541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies come back from the brink.
    Holliger P; Hoogenboom H
    Nat Biotechnol; 1998 Nov; 16(11):1015-6. PubMed ID: 9831027
    [No Abstract]   [Full Text] [Related]  

  • 15. Isotype selection in antibody engineering.
    Salfeld JG
    Nat Biotechnol; 2007 Dec; 25(12):1369-72. PubMed ID: 18066027
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody cocktails: next-generation biopharmaceuticals with improved potency.
    Logtenberg T
    Trends Biotechnol; 2007 Sep; 25(9):390-4. PubMed ID: 17681390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advancing protein therapeutics: current challenges in protein therapeutics -- CHI's Second Annual Conference.
    He M
    IDrugs; 2006 Mar; 9(3):177-8. PubMed ID: 16523380
    [No Abstract]   [Full Text] [Related]  

  • 18. New technologies for the engineering of novel protein therapeutics and the personalization of medicine.
    Dorner AJ; Projan S
    Curr Opin Pharmacol; 2008 Oct; 8(5):598-9. PubMed ID: 18773971
    [No Abstract]   [Full Text] [Related]  

  • 19. Historical development of monoclonal antibody therapeutics.
    Nissim A; Chernajovsky Y
    Handb Exp Pharmacol; 2008; (181):3-18. PubMed ID: 18071939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commercial development considerations for biotechnology-derived therapeutics.
    Marafino BJ; Pugsley MK
    Cardiovasc Toxicol; 2003; 3(1):5-12. PubMed ID: 12668886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.